This product is a cyclic non-specific anticancer drug that acts directly on DNA, mainly cross-linking between and within the chains of cell DNA, destroying DNA and inhibiting tumor growth.

This product is a second-generation sulfonylurea oral hypoglycemic drug. It can promote the secretion of insulin by pancreatic beta cells and enhance the effect of insulin on target tissues; it can also stimulate pancreatic alpha cells to inhibit the secretion of glucagon, inhibit the decomposition of liver glycogen, and promote muscle utilization and consumption of glucose.

This product is a monoamine oxidase inhibitor antidepressant. It works by reversibly inhibiting type A monoamine oxidase in the brain, thereby increasing the levels of norepinephrine, dopamine and 5-hydroxytryptamine in the brain, playing an antidepressant role. It has the characteristics of fast action and rapid recovery of monoamine oxidase activity after discontinuation of the drug.

It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.

It is a cell cycle-specific antitumor drug that inhibits the polymerization of intracellular tubulin, prevents the formation of spindles in the mitosis of proliferating cells, and stops cell division at the metaphase of mitosis. This product has a broad antitumor spectrum for transplanted animal tumors and has no complete cross-resistance with vinblastine and vincristine.